Overview

Liposomal Bupivacaine (Exparel) for Postoperative Pain Control for Open and Laparoscopic Abdominal Hernia Repair

Status:
Completed

Trial end date:
2017-01-01

Target enrollment:
0

Participant gender:
All

Summary

The purpose of this study is to learn how well Liposomal Bupivacaine (Exparel™) controls post-operative pain in patients undergoing both open and laparoscopic (minimally invasive) abdominal hernia repair surgery.

Phase:

Phase 4

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Michael Moncure, MD

Collaborator:

Pacira Pharmaceuticals, Inc

Treatments:

Bupivacaine
Ketorolac
Ketorolac Tromethamine

Criteria

Inclusion Criteria:

- Patients scheduled to undergo an open or laparoscopic abdominal hernia repair.

- Ability to provide informed consent, adhere to study visit schedule, and complete all
study assessments.

Exclusion Criteria:

- Patients with a history of hypersensitivity or idiosyncratic reactions or intolerance
to any local anesthetic, opioids or ketorolac.

- Patients who abuse alcohol or other drug substance.

- Patients who are on chronic opioid therapy (taken an opioid 5 of the last 7 days).

- Patients with severe hepatic impairment.

- Patients currently pregnant.